Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting 2.80. At the close of trading, the stock’s price was $0.93, to imply an increase of 0.08% or $0.0 in intraday trading. The ITRM share’s 52-week high remains $3.02, putting it -224.73% down since that peak but still an impressive 12.9% since price per share fell to its 52-week low of $0.81.

Analysts have given a consensus recommendation of Buy for Iterum Therapeutics Plc (ITRM), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ITRM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.

Iterum Therapeutics Plc (NASDAQ:ITRM) trade information

After registering a 0.08% upside in the last session, Iterum Therapeutics Plc (ITRM) has traded red over the past five days. The 5-day price performance for the stock is -5.50%, and -28.32% over 30 days. With these gigs, the year-to-date price performance is -47.36%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 29.27% for the past 5-year period. While 2025 is set for a 57.87% return in earnings, projections for the next 5 years are at 55.20% annually.

ITRM Dividends

Iterum Therapeutics Plc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 12.37 shares. This is just over 0.03% of the total shares, with a market valuation of $11526.0